Os Therapies INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
AMEX
OSTX
Os Therapies INCThomas A. Satterfield, Jr. has increased his beneficial ownership in OS Therapies Incorporated to 9.4% of common stock, including convertible preferred shares and warrants.
AMEX
OSTX
Os Therapies INCAyala Pharmaceuticals, Inc. has filed a Schedule 13G, reporting a 9.99% beneficial ownership stake in OS Therapies Incorporated, holding 2,164,215 shares of common stock.
AMEX
OSTX
Os Therapies INCSCHEDULE 13G/A: Thomas A. Satterfield, Jr. Discloses 5.9% Passive Stake in OS Therapies Incorporated
Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, reporting a 5.9% beneficial ownership stake in OS Therapies Incorporated as of December 31, 2024.